Every round on record, with the sources behind each and the investors on them.
GeneQuine Biotherapeutics develops gene therapies for various healthcare applications, targeting the biotech market.
genequine.comHamburg, GermanyBiotech
1 source
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source names both funds as investors but does not identify a lead investor.; not on the page it cites, so not applied: amount
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Seed [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | n/a | 2012-11-12 | not stated | No recent discussion |
1 source [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 source The source names both funds as investors but does not identify a lead investor.; not on the page it cites, so not applied: amount | ||||
GeneQuine Biotherapeutics (now GQ Bio Therapeutics) develops locally administered gene-therapy treatments and the vector platform behind them for patients with osteoarthritis and other chronic musculoskeletal diseases.
Its HCAd platform is designed to deliver large or multiple genes locally and efficiently, with scalable manufacturing, targeting osteoarthritis and other chronic musculoskeletal diseases where the pages describe substantial unmet need. The bet has moved beyond preclinical promise: Pacira's 2024 Phase 1 update reported sustained improvements in knee pain, stiffness and function through 104 weeks for PCRX-201, and Pacira acquired the remaining 81% of GQ Bio for approximately $32 million in 2025.
Checked against 8 sources 2d ago
Also named as backers in company research: Pacira BioSciences, Inc., Noshaq SA, Samum Vermögensverwaltungs GmbH, the investment bank of the state of Brandenburg (Germany)
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Series A financing | €5.4 million | 2021-01-26 | Pacira BioSciences, Inc. | |